Purpose: Information regarding antimicrobial prophylaxis (AMP) for gastric cancer surgery is limited. The present study investigated the efficacy of single-dose AMP for the prevention of surgical site infection (SSI) in patients undergoing gastrectomy for gastric carcinoma. Materials and Methods: Between 2011 and 2013, 1,330 gastric carcinoma surgery patients were divided into two AMP administration groups depending on the duration of treatment. Postoperative outcomes including morbidity and SSI were compared between the two groups overall and in matched patients. Risk factors for SSI were analyzed. Results: The extended group (n=1,129) received AMP until postoperative day 1 and the single-dose group (n=201) received singledose AMP only during an operation. Postoperatively, there were no significant differences between the two groups with respect to overall morbidity, mortality, or length of hospital stay. The SSI rate of the single-dose group was not significantly different from that of the extended group overall (4.5% vs. 5.5%, respectively, P=0.556) or in matched patients (4.5% vs. 4.0%, respectively, P=0.801). There was no increase in the SSI rate of the single-dose group compared to the extended group in subgroups based on different clinicopathological and operative factors. Univariate and multivariate analyses revealed male gender, open surgery, and operating time (≥180 minutes) as independent risk factors for SSI. Conclusions: Single-dose AMP showed no increase in the postoperative SSI rate compared to postoperative extended use in patients undergoing gastrectomy for gastric carcinoma. The efficacy of single-dose AMP requires further investigation in randomized clinical trials specific to gastric cancer surgery.
Introduction
Surgical site infection (SSI) is the most common nosocomial infection among surgical patients with an incidence of up to 20% after major abdominal surgeries. 1, 2 As for gastric cancer surgery, the incidence of SSI is reported to be 5% to 20% depending on the patient population, operation type, and the operational definition of SSI according to previous studies. [3] [4] [5] [6] Antimicrobial prophylaxis (AMP) can effectively prevent SSI in gastric cancer surgery;
however, the optimum duration of prophylaxis remains uncertain.
Although current guidelines commonly recommend single-dose AMP for gastrointestinal surgery, [7] [8] [9] [10] [11] [12] most published studies regarding AMP in abdominal surgeries have focused on either biliary or colorectal surgery as opposed to AMP for gastric cancer surgery. [13] [14] [15] Evidence for the efficacy of single-dose AMP for gastric cancer surgery is very limited. Within the last decade, two small random-
Operative procedures and perioperative care
Patients underwent radical subtotal or total gastrectomy with lymph node dissection (LND) as described by the Japanese gastric cancer treatment guidelines. 20 Laparoscopic gastrectomy was indicated for mucosal or submucosal cancers unsuitable for endoscopic resection. Billroth I gastroduodenostomy was the primary reconstruction procedure for subtotal gastrectomy, and Billroth II and
Roux-en-Y gastrojejunostomy were alternatives. After total gastrectomy, Roux-en-Y esophagojejunostomy was performed using a circular stapler in most cases.
Patients in both groups were managed perioperatively using the same standardized protocol of CNUHH. Neither preoperative mechanical bowel preparations nor nasogastric tubes were used.
Briefly, preoperative fasting was avoided until the night before the operation. Intraoperative normothermia was maintained using a warm air blanket. An abdominal drain was not routinely inserted, but was inserted in selected patients. Postoperatively, patients started oral feeding on POD 1 or 2, and restricted intravenous fluid
) was administered for 3 to 4 PODs. Patients were usually discharged from the hospital on POD 6 to 8.
Data collection
Using a prospectively constructed database, we retrospectively reviewed patients' baseline demographic features, operative outcomes, pathological reports, and hospital courses, including postoperative complications. Pathological stages were recorded on the basis of the 7th edition of the Union for International Cancer Control
Tumor Node Metastasis (TNM) classification. 21 Complications or deaths during hospitalization or within POD 1 to 30 were defined as morbidity and mortality. Regarding postoperative complications, those associated with the operative field were considered local, and others were regarded as systemic. The type and severity of each postoperative complication were recorded according to the institutional guidelines of surgical complications after gastric carcinoma.
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SSI was defined and classified on the basis of the National Nosocomial Infections Surveillance system. 2 Briefly, an SSI was defined as an infection occurring within 30 days after an operation that appeared to be related to the operative procedure. SSIs were further classified into superficial incisional (i.e., affecting the skin and subcutaneous tissue), deep incisional (i.e., affecting the deeper soft tissues of the incision), and organ/space (i.e., affecting the any part of the anatomy other than the incision). Regarding organ/ space SSIs, both primary abdominal infections and secondary infections due to any other reason requiring therapeutic antibiotics or intervention were included. Values are presented as mean±standard deviation or number (%). BMI = body mass index; COPD = chronic obstructive pulmonary disease; LC = liver cirrhosis; LND = lymph node dissection; TNM = Tumor Node Metastasis. *LND according to the Japanese gastric cancer treatment guideline 2010 (ver. 3). † TNM stage was based on the 7th edition of the American Joint Committee on Cancer staging system. 
Statistical analyses

Comparison of surgical site infections in matched groups
Because patients in the two AMP groups showed some heterogeneity in their baseline characteristics, we individually matched patients in the single-dose group with patients in the extended group using the propensity score matching method based on clinicopathological and operative factors in order to compare postoperative morbidity and SSI rates. Table 4 shows that matched patients were well balanced with respect to age, sex, BMI, comorbidity, operative procedures, operating time, and TNM stage. In matched samples, patients in the single-dose group showed no increase in the SSI rate compared to patients in the extended AMP group (4.5% vs. 4.0%, respectively, P=0.801). Additionally, there were no significant differences between the single-dose and extended AMP groups with respect to overall morbidity (both 12.9%, P=1.000), mortality (0% vs. 0.5%, respectively, P=1.000), or the length of the hospital stay (7.9 vs. 8.0 days, respectively, P=0.908).
Risk factors for surgical site infection
The risk factors for SSIs determined in the overall patient population by univariate and multivariate analyses are summarized in Table 5 . In the univariate analysis, age, BMI, comorbidity, operative approach, extent of gastric resection and LND, operating time, combined organ resection, TNM stage, and the duration of AMP administration were compared between the two groups. Male sex, 
Discussion
There is very limited information available regarding the efficacy of single-dose AMP for gastric cancer surgery. Furthermore, in spite of the recommendation for a single dose AMP in current guidelines, postoperative extended use of AMP is still prevalent after gastric cancer surgery, especially in Korea and Japan. 18, 19 Despite the inherent limitations of the retrospective study design, the present study demonstrated that single-dose AMP is as effec- ditionally, these trials considered a broad range of gastrointestinal surgeries from simple gastrostomy to complex pancreaticoduodenectomy, making it difficult to apply study findings specifically to gastric cancer surgeries. Furthermore, some regional differences are apparent in the recommendations pertaining to AMP for gastrointestinal surgeries. In the guidelines of the Japanese Association for Infectious Diseases, it is recommended that AMP can be extended for up to 1 to 3 days after gastrointestinal surgery due to the high degree of heterogeneity in surgical practices between Eastern and
Western countries, such as a high prevalence of drain use and extensive LND. 16 The optimum duration of AMP for gastric cancer surgery remains to be elucidated, and more evidence supporting the efficacy of single-dose AMP for gastric cancer surgery is required.
Single-dose AMP has been shown to be as effective as its extended use for gastric cancer surgery in small retrospective studies. 24 Although the patients in this study were assigned to different AMP regimens according to when they were treated, the two study groups exhibited some differences in baseline characteristics including age, operative procedures, and tumor stage. The propensity score matching method is useful in this circumstance in order to reduce the impact of heterogeneity on the estimation of causal treatment effects in the observational data. 23 To balance these differences between the two groups, patients were individually matched based on clinicopathological and operative factors, and operative outcomes and SSI were compared between the matched patient groups. The SSI rate was still not significantly different between the matched patients in the single-dose and extended groups (4.5% vs. 4.0%, respectively, P=0.801).
The present study had some limitations, including an analysis inherently limited by possible selection bias and low generalizability due to the retrospective, single center study design. Based on the results of the present study, a multi-institutional clinical trial investigating the efficacy of single-dose AMP for gastric cancer surgery is planned. In addition, there were relatively fewer patients in the single-dose group as compared to the extended group, which may have undermined the comparability of the two groups. Lastly, patients in each group underwent gastrectomy during a different period. Therefore, advances in surgical techniques and instruments, as well as increased experience, may have affected the study results such that the rate of SSIs in the single-dose group was similar to that of the extended group.
In conclusion, the present study demonstrated the efficacy of single-dose AMP for preventing SSIs after radical gastrectomy for gastric carcinoma. These results confirm and extend findings from previous research supporting single-dose AMP for gastric cancer surgery, and highlight that the current practice of prolonged postoperative use of AMP in Asia is not evidence-based. Finally, the efficacy of single-dose AMP needs be investigated further, specifi-
